Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI

Conclusion: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.
Source: Alzheimer Disease and Associated Disorders - Category: Geriatrics Tags: Original Articles Source Type: research